The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors

Q Shen1, I P Uray, Y Li

  • 1Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.

Oncogene
|July 20, 2007
PubMed

Insights

Activating protein-1 (AP-1) regulates breast cancer cell growth by controlling cyclin D and E2F expression. Blocking AP-1 with Tam67 inhibits proliferation by downregulating key cell cycle genes.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Activating protein-1 (AP-1) is a transcription factor crucial for cell growth and malignant transformation.
  • Previous studies showed that a dominant-negative cJun mutant (Tam67) inhibits breast cancer cell growth by blocking AP-1 activity.

Purpose of the Study:

  • To investigate the mechanisms by which AP-1 blockade by Tam67 affects cyclin D1 and E2F expression in breast cancer cells.
  • To elucidate the role of AP-1 in regulating cell cycle progression and proliferation in breast cancer.

Main Methods:

  • Utilized MCF-7 breast cancer cells treated with Tam67.
  • Assessed transcriptional activity of cyclin D1 promoter using reporter assays.
  • Measured mRNA and protein levels of AP-1, E2F family members, and cyclins.
  • Performed chromatin immunoprecipitation and supershift assays to analyze protein-DNA interactions.

Main Results:

  • AP-1 blockade by Tam67 suppressed cyclin D1 transcription via AP-1 and E2F binding sites.
  • Tam67 reduced expression of E2F1 and E2F2, and decreased E2F1 binding to the cyclin D1 promoter.
  • AP-1 blockade altered the expression of various E2F-regulated cell cycle genes, including cyclins E, A, B, D3, G2, and I.

Conclusions:

  • AP-1 transcription factor plays a significant role in regulating cyclin D1 and E2F expression.
  • AP-1 blockade disrupts cell cycle progression and inhibits breast cancer cell proliferation.
  • The findings highlight AP-1 as a potential therapeutic target for breast cancer treatment.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Molecular Factors Affecting Cell Division01:27

Molecular Factors Affecting Cell Division

Several external and internal factors influence the initiation and inhibition of cell division. For instance, the death of nearby cells or the release of human growth hormone (hGH) promotes cell division. In contrast, lack of hGH or crowding of cells can inhibit cell division.
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...